ASH News Daily 2013 - Day 3 - (Page B-23)
ASH News Daily
Monday, December 9, 2013
Page B-23
®
FocuS on
traineeS
Trainee Events
«« From Page B-15
complimentary refreshments.
Hours:
Monday, December 9
7:00 a.m. to 5:00 p.m.
Tuesday, December 10
7:00 a.m. to 12:00 noon
Are You a Postdoctoral Fellow
Residing Outside North America?
Consider participating in ASH's
International Post-Doctoral Fellows (IPDF) program, which allows postdoctoral fellows to access valuable ASH resources at no
charge for up to four years. The
program is open to postdoctoral
fellows with a PhD, MD, or equivalent medical degree, who reside
outside Canada, Mexico, or the
United States; register for the ASH
annual meeting as a non-member
in training; and are enrolled in an
approved hematology or oncology training program. Benefits
include a complimentary online
subscription to Blood, online access
to Hematology (the Education Program), and online access to ASH's
award-winning member newsletter, The Hematologist.
Are You a North American
Undergraduate or Trainee, But
Not a Member of ASH?
Fellows: ASH offers a deeply discounted Associate membership
for those in approved hematology
or hematology/oncology training
programs.
Medical Students, Graduate Students,
and Residents: ASH now offers a com-
Trainee Simultaneous
Didactic Sessions
Today, 12:15 - 1:15 p.m.
During lunch, ASH will offer
didactic sessions designed to provide trainees with an overview of
timely and relevant career-oriented issues. A boxed lunch will be
provided. Space is available on a
first-come, first-served basis. As
seating is limited, attendees are
strongly encouraged to arrive early. No additional participants will
be allowed in the rooms once these
sessions are filled.
Chair: Ted Wun, MD, University
of California - Davis, Sacramento,
CA
Phase 3 Trial
Now recruiTiNg
assessing brentuximab vedotin in
Frontline Peripheral T-cell lymphomas
consider echeloN-2 when making a treatment plan
Patients
Giving a Scientific Presentation
Speaker: Theodore Warkentin,
MD, McMaster University, Hamilton, Ontario, Canada
Presentation of one's scholarly
work is an essential task for an academic career and the effective communication techniques that allow
for engaging presentations need to
be learned and honed over time.
This session will cover presentation styles and proper construction
of slides and posters, highlighting
common presentation pitfalls as
well as tactics to help engage an
audience. Attendees will learn how
to make the most of opportunities
to present their scholarly work and
receive valuable feedback.
Practical Biostatistics 101
Speaker: Lillian Sung, MD, PhD,
The Hospital for Sick Children, Toronto, Ontario, Canada
This session is designed to help
translate the complexities of statistics into relevant clinical applications and will provide a practical
clinician perspective on key biostatistical concepts and terms as well
as basic study designs, touching on
relevant clinical endpoints with an
emphasis on clinical examples.
plimentary student membership.
Undergraduate Students: Consider participating in ASH's North
American Undergraduate Student
Benefit program designed for trainees in the United States, Canada,
and Mexico who are undergraduate or graduate students, residents
(in post-graduate years 1-3 for Canadians), or PhD candidates. This
program provides undergraduate
students with a complimentary
online subscription to Blood, advance annual meeting notifications,
and eligibility for reduced meeting
registration at the non-member-intraining rate.
CD30-positive mature (peripheral)
T-cell lymphomas, including
systemic ALCL (N = 300)*
Select inclusion criteria:
* Newly diagnosed
* Measurable disease, as
defined by both of the
following:
- FDG-avid disease by PET
- CT tumor burden ≥1.5 cm
* ECOG performance
status 0 to 2
Investigational arm
A+CHP regimen† (6-8 cycles)
Brentuximab vedotin
1.8 mg/kg IV on day 1 of each
21-day cycle, plus placebo
replacement for vincristine
Endpoints
Primary endpoint
* Progression-free
survival (PFS)
Secondary endpoints
Standard arm
CHOP regimen† (6-8 cycles)
Vincristine 1.4 mg/m2 IV on
day 1 of each 21-day cycle,
plus placebo replacement for
brentuximab vedotin
* Overall survival
* Overall response rate
* Safety and tolerability
*Eligible subtypes include anaplastic lymphoma kinase (ALK)-positive systemic anaplastic large cell lymphoma (ALCL) with an
International Prognostic Index (IPI) score of ≥2; ALK-negative systemic ALCL; peripheral T-cell lymphoma, not otherwise specified
(PTCL-NOS); angioimmunoblastic T-cell lymphoma (AITL); adult T-cell leukemia/lymphoma (ATLL); enteropathy-associated T-cell
lymphoma (EATL); and hepatosplenic T-cell lymphoma.
Cyclophosphamide 750 mg/m2 and doxorubicin 50 mg/m2 will be administered IV on day 1; 100 mg oral prednisone will be
administered on days 1-5 of each 21-day cycle.
†
To learn more about echeloN-2
* Visit the Seattle Genetics Medical Affairs booth
Eligible patients must
be treatment-naïve
* Contact Seattle Genetics Medical Information
at 866.333.7436 (US only)
STOP
* E-mail clinicaltrials@seagen.com
CHOP
BEFORE
* Visit clinicaltrials.gov (NCT01777152)
seattlegenetics.com
Seattle Genetics and are uS registered trademarks of Seattle Genetics, inc.
Other trademarks are property of their respective owners.
MillenniuM and
are registered trademarks
of Millennium Pharmaceuticals, inc.
Other trademarks are property of their respective owners.
© 2013 Seattle Genetics, inc., Bothell, WA 98021
All rights reserved.
Printed in uSA
Millennium Pharmaceuticals, inc., Cambridge, MA 02139
Copyright © 2013, Millennium Pharmaceuticals, inc. All rights reserved.
17010_sgncln_fa1_echelon.indd 1
uSM/BVM/2013/0025(1)
10/30/13 1:17 PM
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 3
Table of Contents
ASH News Daily 2013 - Day 3
https://www.nxtbookmedia.com